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Abstract  
Background: The excess morbidity and mortality associated with schizophrenia is partly due to cardiovascular diseases resulting from the 
complex inter-relationships between unhealthy life style including, metabolic problems, and the metabolic risks associated with the use of 
psychotropic medications. The current project involves patients with schizophrenia, their informal care providers and the health 
professionals, who treat them. Aims; Our primary aim in the Monitoring and Management of Cardiovascular Risk factors In 
Schizophrenia (MOMACRIS) Project is to determine whether an integrated mental and physical health care approach that involves 
patients with schizophrenia, their informal care providers and the health professionals who treat them, would improve identification, 
management and outcome of cardio-metabolic risk factors in these patients. Methods; We assess the knowledge and attitude of patients, 
their informal care providers and health care professionals about general cardiometabolic risk factors and life style modification. We also 
assess the current cardiometabolic monitoring and management practices by the health care professionals who treat patients with 
schizophrenia and we identify any barriers that may be limiting what theses care professionals do. At baseline we assess the needs for 
improved cardiometbolic monitoring. Thereafter we carry on culturally-tailored psycho-educational based interventions directed at the 
patients with schizophrenia, their informal care providers and health care professionals following the baseline assessments of the 
identified needs for improved cardiometbolic monitoring. This will be achieved in an integrated collaborative effort between psychiatrists, 
psychologists, general/family physicians (or internists/endocrinologists), dieticians and physiotherapists. Conclusion; Morbidity and 
mortality from cardiometabolic risk in schizophrenia is higher than chance occurrence. Identification and management of these risk 
factors seem to be hampered by a number of barriers despite years of developing one guide line after another. There is need to re-evaluate 
the current knowledge, beliefs and practice of everyone concerned with schizophrenia. 
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1. Running Text 
MOMACRIS study 
1.1. Background and Rationale 
Morbidity and mortality in patients with schizophrenia is 
very high. All forms of physical diseases contribute to this 
disproportionate burden but of particular importance are 
cardiovascular and metabolic (cardio metabolic) diseases. 
Obesity, glucose metabolism dysregulation, 
atherogenicdyslipideamia and cigarette smoking are 
interconnected cardio-metabolic risk factors that are about 
twice as prevalent in patients with schizophrenia than 
individuals from the general population (Correll, 2007). 
High risk for CVD and its associated premature mortality 
among people with schizophrenia is commonly attributed 
to low socio-economic status, behavioural factors and 
treatment factors. There may also be possible genetic 
vulnerability of this patient population to develop 
metabolic problems (Gough et al 2005 Peet 2004, Hasnain 
et al 2009, Roick et al 2007, Koola et al 2012, Vancampfort 
et al 2010, Beary&Mildgust 2012, Wildgust &Beary 2010.). 
In a recent publication, Larsen et al ( 2013) reported that 
cardiovascular diseases, diabetes mellitus and obesity were 
increased in patients with schizophrenia in the three 
cultural settings of Africa (Nigeria), Japan, and Western 
Europe ( Demark, Germany and Switzerland). Life style 
diseases were described in all the cultures. In a literature 
review on co- morbid physical diseases in schizophrenia, 
Leucht et al (2007) reported that people with schizophrenia 
have higher prevalence of HIV infection, hepatitis, 
osteoporosis, altered pain sensitivity, sexual dysfunction, 
obstetric complications, cardiovascular diseases, 
overweight, diabetes, dental problems, and polydipsia than 
the general population. They concluded that the increased 
frequency of physical diseases in schizophrenia might be 
accounted for by factors related to schizophrenia and its 
treatment, the unsatisfactory organization of health services, 
the attitudes of medical doctors, and the social stigma 
ascribed to the schizophrenic patients. 
Patients with schizophrenia are thus predisposed to 
cardiovascular disease and die of it 20 years sooner than 
individuals from the general population ( Allison et 2009, 
De Hert et al 2009, Hennekens et al 2005, Tiihonen et al 
2009 ). The cardiovascular disease related mortality gap 
between patients with schizophrenia and the general 
population has not changed over the last couple of decades 
( Hennekens et al 2005, Tiihonen et al 2009). In a literature 
search to explore the distribution of standardized mortality 
ratios (SMRs) for people with schizophrenia, Saha et al 
(2007) reported that the SMRs for all-cause mortality have 
increased during recent decades (P=.03) indicating a 
substantial gap between the health of people with 
schizophrenia and the general community. This differential 
mortality gap has worsened in recent decades. 
This is reflective of failure of current strategies to 
improve the cardio-metabolic care and outcome of patients 
with schizophrenia. 
Guidelines on metabolic screening and monitoring of 
patients with schizophrenia receiving antipsychotic 
medications have been available for several years 
( American Diabetes Association 2004, De N et al 2007, 
Expert Group 2004 ) but their implementation in clinical 
practice so far has been limited (Barnes et al 2007, Mackin 
et al 2007,Nasrallah et al 2006, De Hert et al 2011, Mitchell 
et al 2012)due to a complex set of reasons pertaining to 
physician, patient and system related factors(Lambert & 
Newcomer 2009, Ohaeri & Akanji 2010). It has been 
shown that even when patients with schizophrenia have 
been diagnosed with metabolic problems their medical care 
is less adequate than the care of those without 
schizophrenia ( Hippisley-Cox et al 2007, Roberts et al 
2007). Clearly, various guidelines and consensus statements 
have not been effective in adequately addressing the 
cardiometabolic health of people with schizophrenia. There 
is therefore a pressing need to re-evaluate our 
understanding of this problem of non-functioning 
preventive medical exercise and our approach to tackling it. 
1.2. Aim of the Study 
The primary aim of this study is to determine if 
educating health professionals working with patients with 
schizophrenia about the cardio-metabolic health care of 
these patients, and offering them a focused structure of 
work in collaboration with one other in routine clinical 
practice would improve screening for and monitoring, 
management and outcome of the cardio-metabolic risk 
factors. The specific major components of the study are: 
1 To compare the attitude of health professionals, 
patients, and patients’ informal care providers to 
adiposity, and unhealthy lifestyle. 
2 To assess the current practice of cardio-metabolic 
health management of patients with schizophrenia 
by health professionals as to screening and 
monitoring for metabolic risk factors, metabolic 
problems and unhealthy lifestyle. 
3 To identify the patient, physician, and system-
related barriers that prevent or limit patients with 
schizophrenia from receiving effective care for their 
cardio- metabolic health. 
4 To evaluate the effects of cardiometabolic care of 
patients with schizophrenia by collaboration 
between psychiatrists, general practitioners/family 
physicians or internists, dieticians, and 
physiotherapists or psychologists. 
1.3. Global and Transcultural Perspective 
Virtually all available consensus statements and guidance 
on cardiometabolic risk factors in patients with 
schizophrenia have emanated from works in Western and 
developed countries. Our study includes one centre in a 
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developed country and four centres in middle and low 
income countries (LAMIC), with different gross domestic 
products (GDPs) and systems of health care. It will provide 
information about how the cardiometabolic problem of 
patents with schizophrenia is viewed and tackled across 
different cultures and economies. 
Cultural influences lead to difference in the habitual 
consumption of certain foods and in traditions and methods 
of preparation. Some diets that contain essentially the same 
core ingredients may assume different names in different 
cultures. 
Different cultures adopt different diets and eating 
patterns. In some cultures, for example, fried foods, biscuits 
and ham hocks might be popular whereas in others such as 
those of many Asian cultures, menus may stress lower-fat 
foods and lots of vegetables. Cultural views about the 
health benefits and risks of various foods also differ. 
Furthermore, there are cultural differences in the perception 
and involvement in physical exercises. Whereas purposely 
planned physical exercises may not be fashionable in some 
cultures, the types and forms of work may involve very 
vigorous physical activities. 
General and mental health manpower availability and 
distribution also differs across cultures and communities. 
These differences pose enormous challenges in studies of 
the like of MOMACRIS, necessitating inevitable flexibility 
in the analyses of the results and eventual emanating 
recommendations. 
1.4. Hypothesis 
We hypothesised that the cardiometabolic care and 
outcome of patients with schizophrenia could be improved 
by 1) improving awareness among the health professionals, 
patients and their care-providers about the increased 
cardiometabolic risk of these patients, 2) identifying and 
addressing the barriers to their effective cardio-metabolic 
care, and 3) integrating the cardiometabolic care with the 
psychiatric care by collaboration between professionals 
with expertise in this area. 
2. Materials and Methods 
2.1. Study Design 
The current study is being carried out in a naturalistic 
setting. Retrospective, prospective and cross sectional data 
are collected in three continents located in Belgium, India, 
Nigeria, and Pakistan, Each of the participating centres has 
access to: 
• Primary care physicians or internists with interest 
and expertise in metabolic problems 
• laboratory facilities 
• resources to maintain, handle and organize data, 
and 
• health professionals skilled in offering counselling 
concerning physical activity/exercise, diet, 
cognitive therapy, smoking cessation, and substance 
use disorders 
We employ a modified stepped wedge design. The 
planned intervention is rolled-out sequentially to the trial 
participants (i.e. clusters of patients with schizophrenia, 
their family care providers and health care professionals) 
over different time periods across the participating centres. 
The different clusters receive the interventions once each 
centre completes the phase two of the study 
2.2. Sample Size 
We employed a most conservative estimate and assumed 
equality in all the clusters across the participating centres 
(Hayes & Benneth S 1999). We used two previous studies 
( Moratto et al 2009, Bobes et al 20110 ) that reported on 
the rates of metabolic monitoring before and after 
consensus statements on cardiometabolic risk factors in 
patients with severe mental illness. We estimated that at 
80% power, each participating would need about fifty 
patient participants. We used a total population survey for 
all the mental health care professionals in each centre.  
2.3. Participants 
The study has three groups of subjects: (i) Patients with a 
clinical (DSM-IV) diagnosis of schizophrenia made by the 
local mental health experts. (ii) Care-providers (spouse, a 
family member or a friend) of these patients, as nominated 
by the patient and available to participate in the study. The 
care-providers are henceforth referred to as “patient care-
providers” to differentiate them from the health-care 
providers (iii) Health care professionals (psychiatrists, 
psychiatric nurses, psychiatric social workers, occupational 
therapists, clinical psychologists, physiotherapists, 
dieticians, internists, primary care physicians or any other 
health professionals involved in the care of the participating 
patients. 
In each participating centres where patients are involved, 
an attempt is made to select a sample reasonably 
representative of the typical schizophrenia population seen 
in the centre. A simple random probabilistic sampling is 
employed to select the participants from the pool of 
patients with schizophrenia in each centre. The factors for 
consideration include the profile of the patients with respect 
to age, gender, duration of illness, location of origin within 
the study centre and any other unique factors in any centre. 
Given the different reported ranges of non-measurement of 
cardio metabolic parameters, and the presence of gluco-
lipid dysregulation in patients with schizophrenia and the 
referral rates by psychiatric care providers of patients who 
have schizophrenia with cardiometabolic diseases to other 
health care providers, we estimated the sample size of 
patients with schizophrenia that would be needed. We took 
note of the fact that our study centres would likely have 
very poor rates of cardiometabolic monitoring and 
documentation. We assumed that on the average, complete 
cardiometabolic monitoring and documentation in patients 
with schizophrenia may be about 7% (Mackin, Bishop & 
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Watkinson 2007). With an error of estimate (precision) of 
5%, we expected that we would need a minimum of 100 
patient participants. On the other hand, we speculated that 
in most of our participating centres, there would be only 
few mental health care professionals (involved in the direct 
care of patients with schizophrenia). Consequently, we aim 
to recruit all the mental health care professionals in each 
centre. 
Each centre, would select by systematic probabilistic 
random sampling, 50 or more adult (≥ 18 years) patients 
with schizophrenia, who had received psychiatric care for a 
minimum of six months prior to the study. All patients 
already participating in any ongoing clinical trial are 
excluded. Patients with acute and/or unstable medical 
conditions (e.g., unstable coronary heart disease, recent 
myocardial infarction, acute/severe hyperglycaemia, acute 
hepatic or renal problems, poorly controlled seizure 
disorder, recent cerebrovascular accident or an acute 
infection) are not eligible to participate. 
The study conforms to the requirements for 
investigations involving human subjects (Helsinki 
Declaration). All the participating centres have approval 
from their appropriate clinical research ethics committee 
(institutional review board. 
The purpose of the study was verbally explained to all 
participants and only participants who give signed 
informed consent are included. Patients who have acute 
psychotic disturbance during the study and who are deemed 
not to have the capacity to sign an informed consent, are 
not eligible to participate. 
2.4. Instruments and Measures 
Using structured questionnaires developed and adapted 
from previous studies ( Lambert & Newcomer 2009, (20) 
Bocquier et al 2005, Deurenberg-Yap et al 2001, Merz et al 
2002, Osler et al 2001,Pirkis et al 2005,.Puig et al 2005, 
Spearing et al 1997, Zibaeenezhad 2007), we collected data 
retrospectively, cross-sectionally and prospectively. There 
are a total of nine sets of questionnaires, subdivided as 
different sections , designated as FORMS A, B, C, D, E, F, 
G, H and M. Each questionnaire subgroup contains the 
demographic profile of the participants and a rating of the 
reliability of the interview (worthless interview=0, serious 
doubts=1, some doubts=2, no or few doubts=3, or perfectly 
reliable=4). 
Most of the FORMS are completed at baseline, and after 
an educational intervention. 
FORM A is specifically designed to collect information 
that would evaluate the health professionals’ knowledge, 
views and practices about screening and monitoring of 
patients with schizophrenia for metabolic and 
cardiovascular risk factors and for their unhealthy lifestyle. 
It is meant only for health care providers. It is a 33-item 
questionnaire, where each stem question has five possible 
responses ranging from strongly agree to strongly disagree. 
Scores range from 33-165; lower scores reflect more 
positive attitude. 
FORM B is designed to assess the barriers to the 
metabolic care of patients with schizophrenia as identified 
by the health professionals working with these patients in 
their particular context. It contains 28 question items, 
worded to elicit opinions like in FORM A. The questions 
address both personal and institutional factors that could 
interfere, delay, disrupt or discourage metabolic monitoring 
in patients with schizophrenia. 
FORMS C and D are designed to enable comparison of 
the health professionals, patients, and patients’ informal 
care-providers on their views about cardio-metabolic risk 
factors including adiposity, exercise, smoking, caffeine 
consumption and alcohol consumption. 
FORM C is meant specifically for health professionals 
whereas FORM D is for patients and patients’ informal care 
providers. The questionnaires (C and D) have a set of items 
that assess knowledge about the cardio-metabolic risk 
factors and another set of questions that assess practices for 
healthy lifestyle. Taken together, these two sets of questions 
reflect the degree of congruity between individuals’ 
knowledge and practices about cardio-metabolic risk 
factors. Weight and BMI of all participants are measured at 
baseline and after interventions. . For all groups, the extent 
of exercise, efforts to eat healthily, and changes in smoking 
and consumption of alcohol were also measured. It also 
consist of the International physical activity questionnaire 
(IPAC) 
2.5. The International Physical Activity 
Questionnaire (IPAQ) 
The development of an international measure for 
physical activity commenced in Geneva in 1998 and was 
followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000 
(Ralph- Maddison et al 2007.). 
The International Physical Activity Questionnaires 
(IPAQ) comprises a set of 4 questionnaires. Long (5 
activity domains asked independently) and short (4 generic 
items) versions for use by either telephone or self-
administered methods are available. We use the seven item 
version of IPAQ in a face to face interview and adopt the 
last seven days as the period of reference. The IPAQ shows 
good psychometric properties in patients with 
schizophrenia (Faulkner et al 2006). 
FORM D is the equivalent of FORM C designed for 
patients with schizophrenia or their informal care providers. 
It eliminates all clinical questions that would be 
inappropriate for non health professionals. It contains the 
IPAQ as in FORM C. 
FORM E is an audit questionnaire. It is designed for the 
evaluation of the existing screening, monitoring and 
management practices of cardio-metabolic problems in 
patients with schizophrenia. In each study centre, a review 
of some randomly selected patients’ charts/medical records 
is done at base line. Among other things, the review notes if 
there is any documentation of the diagnosis of 
hyperglycaemia and/or dyslipidaemia, and whether the 
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patient is being treated for these conditions where present. 
The patients whose charts are reviewed have fasting blood 
glucose, and lipid profile measured to determine 1) any 
patients who have cardiometabolic problems but are 
undiagnosed by the treating health professionals, and 2) 
how well the cardiometabolic problem of those who have 
the documented diagnosis is controlled. After the 
intervention phase of the Project, the same data is collected 
again in the same manner. 
FORM F is a Follow-up audit questionnaire. When a 
patient with schizophrenia is found by the treating mental 
health professionals to have a metabolic or cardiometabolic 
problem, it is expected that such a patient will be referred 
to appropriate professionals such as internists of family 
physicians. The physical health professionals are 
conventionally expected to make some recommendations to 
the mental health professionals and the patients on what 
needs be done. The study questionnaire F is designed to 
capture the follow up and treatment adherence with the 
family physician/ general physician/internist 
recommendations. 
Respectively, FORMS G and H are the Clinical Global 
Impression Scale (CGI) ( Spearing et al 1997) and the 
Health of the Nations Outcome Scale (HoNOS) (Pirkis et al 
2005) used for the evaluation of patients’ well 
being/improvement. In all the phases of the study, the 
patients’ symptoms are monitored with the HoNOS and the 
Clinical Global Impression Scale (CGI) along side the 
metabolic monitoring. 
2.6. The CGI 
Clinical Global Impression Scale (CGI) is a brief 
clinician-rated instrument that consists of three different 
global measures (Spearing et al 1997,). The measures 
include: Severity of illness (CGI-S); Global improvement 
(CGI-I); Efficacy index(CGI-E).The CGI has been widely 
utilized as an efficacy measure in clinical drug trials in 
different mental disorders including schizophrenia. It is 
concise and easy to administer (Spearing et al 1997). 
2.7. The HONOS 
The HoNOS was developed partly in response to The 
Health of the Nation policy document and the National 
Health and Community Care Act (Jacobs 2009). The aim 
was to provide a means of recording progress towards the 
Health of the Nation target to improve the health and social 
functioning of people with mental disorders (Jacobs 2009, 
Glover et al. 1997). This resulted in is a 12 item an 
instrument which combines the measurement of psychiatric 
symptoms, hospital service use and „patient based aspects 
such as social functioning. 
HoNOS has been translated into many languages and is 
being widely used in Australia and New Zealand, Canada, 
Denmark, France, Italy, Germany and Norway (Glover et al. 
(1997). 
The 12 HoNOS items are each scored from 0 (no 
problem) to 4 (severe problem) yielding a total score in the 
range of 0 (best) to 48 (worst). Ratings are carried out 
either by an individual psychiatrist, nurse, psychologist, or 
social worker, or by using input from the clinical team. 
Outcome is measured by comparing a patient’s scores at 
two points in time using individual items scores, the 
subscale scores and the total score. 
The subscale items relate to social disability and 
community functioning and the rating period should cover 
the previous two weeks. The HoNOS takes an average of 
between 5 and 15 minutes to complete, depending on the 
experience of the rater and the complexity of the patient’s 
problems (Pirkis et al 2005, Jacobs 2009, Glover et al. 
1997). 
For all participants who undergo any interventions in the 
phase 3 of the study (see below for the description of the 
phases), FORM M is used to monitor personal, physical 
and laboratory variables at base line and at follow up. Use 
of alcohol, cigarette, cannabis and involvement in physical 
activity, is assessed. Anthropometric parameters, blood 
pressure and lipid profiles are measured.  
The therapeutic drugs including the first and second 
generation antipsychotics used by the treating physicians 
will not in any way be interrupted; however, the managing 
doctors will be given the feed back of cardiometabolic 
indices of clinical importance.  
2.8. Measures 
The measures include : Socio demographic data, 
psychiatric history, present treatment, anthropometric 
measures (weight, height, BMI, waist circumference, hip 
circumference, waist-Hip ratio ), blood pressure, laboratory 
tests (cholesterol, triglycerides, HDL/LDL, blood glucose, 
and other relevant lab tests), level of activity, tobacco, drug, 
and alcohol use. The Clinical Global Impression Scale 
(CGI) and Health of the Nations Outcome Study (HoNOS) 
are used to monitor symptoms and well being. All 
laboratory investigations are conducted locally at each 
centre by only one medical/scientific laboratory to ensure 
standard and reliability. 
2.9. Primary Outcome Measures 
The primary outcome measures are a change in 
metabolic monitoring and care by health professionals and 
a change in life style of patients with schizophrenia (diet, 
physical activity/exercise, cigarette smoking and alcohol 
use). 
2.10. Secondary Outcome Measures 
The secondary outcome measures are changes in weight, 
laboratory values and clinical assessments (CGI and 
HoNOS) in the patients with schizophrenia. 
2.11. Study Procedure and Phases 
The study is an open transcultural naturalistic 
multicentre intervention study with “waiting list” and 
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background population comparison groups. The study has 4 
phases. 
Phase 1 is the protocol establishment phase. This phase 
focused on refining and finalizing the study protocol. 
During this phase, we identified and adapted questionnaires 
and instruments from previous studies. We identified 
potential study centres and communicated with the resource 
persons at these centres to determine which centres were 
interested in participating and had relevant resources to do 
so. Initially about twenty centres expressed readiness to 
participate but eventually only five centres actually took 
part in the project. Subsequent to the release of the final 
protocol to the designated local principal investigators or 
centre heads, video, e-mail conferences were conducted to 
achieve agreement about the procedures of the study (and 
to make the participating centres function as a whole by 
gaining familiarity). The Protocol was finalized within 6-12 
months from the date of acceptance of the proposal by the 
World Psychiatric Association, the Sponsor of the Project. . 
An additional period of 3-6 months was granted to 
individual centres to seek approval from their Research 
Ethics Boards or Institutional Review Boards. 
Phase 2 is the baseline data collection phase and takes 
place across all participating centres. In the five centres that 
have completed this phase it lasted about 6 months. The 
specific components of this phase involve: 
1 Comparison between the health professionals, 
patients, and patients’ care-providers for their 
weight, BMI and lifestyle (smoking, exercise, 
caffeine consumption and alcohol consumption), 
and getting a perspective of these individuals about 
adiposity and the health behaviours known to be 
metabolic and cardiovascular risk factors. 
2 Evaluation of the health professionals’ views about 
screening and monitoring of patients with 
schizophrenia for metabolic and cardiovascular risk 
factors and for their unhealthy lifestyle 
3 Evaluation of existing screening, monitoring and 
management practices 
4 Identification of barriers to the metabolic care of 
patients with schizophrenia as reported by the 
health professionals working with these patients. 
Phase 3 is the intervention phase. Psychiatrists, general 
physicians/internists, nutritionists/dieticians and 
cognitive/behavioural therapists or physiotherapists, will 
offer culturally appropriate standard needs-based treatments 
following from phase 2. The exact intervention strategies 
are developed and refined during Phase 1 and their specific 
applications to the relevant study participants is determined 
by the findings of phase 2. We aim to minimize costs by 
employing group approaches whenever practical and 
feasible. The interventions in this phase will be - 
1. Offering education to the members of the mental 
health care professionals in the participating centres 
about: (i) the need for cardio-metabolic screening 
and monitoring of patients with schizophrenia, (ii) 
about the relative metabolic liability of various 
antipsychotic medications and when and how to 
switch them, and (iii) the significance of healthy 
lifestyle interventions to address cardio-metabolic 
risk factors. 
2. When possible, providing guidance and 
encouragement to the centre heads in addressing 
barriers to the cardio-metabolic care of patients. 
3. Availing services of a dietician who will offer 
guidance and education in a group setting following 
established dietary guidelines. 
4. Availing services of a behavioural/cognitive or 
other trained therapist in a group setting, who will 
follow a standard therapy programme across the 
centres to improve physical exercise activity, eating 
healthily, quitting smoking and quitting or 
decreasing caffeine and alcohol consumption. 
5. Switching patients from an antipsychotic 
medication with high metabolic liability to one with 
low metabolic liability. 
6. Availing services of the general physician or 
internist as deemed necessary, for example for the 
control of lipid and or glucose metabolic 
dysregulation. 
Phase 4 would be the follow-up phase. In this phase the 
impact of interventions offered in phase 3 would be 
evaluated. This phase would aim principally at determining: 
1. The impact of educational interventions on the 
knowledge, attitude and practice of the involved 
health professionals about screening and monitoring 
of patients with schizophrenia for cardio-metabolic 
risk factors. 
2. Whether barriers to the metabolic care of patients 
with schizophrenia as identified by the health 
professionals working with these patients changed 
over time, and how effectively the barriers 
identified by them earlier were removed. 
3. Evaluation of the current screening, monitoring and 
management practices will be done to determine 
whether the actual practice of the health 
professionals with respect to cardio-metabolic 
monitoring changed over the study period 
4. Whether the study interventions indirectly 
influenced the personal views about and approach 
of the health professionals, patients and their care-
providers about the significance of healthy lifestyle, 
and impact upon their weight and BMI. 
5. This phase will also identify the barriers to the 
interventions (group dietary counselling, group 
behavioural/cognitive therapy, switching 
antipsychotic medications and management of 
metabolic problems by the physician) of phase two. 
3. Minimum Data Collection 
The study is naturalistic, and represents quality control 
and best practices in the cardio-metabolic health of patients 
with schizophrenia. Centres differ in the amount of data 
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that are collected. The minimum data to be collected 
include anthropometric measures (weight and height), 
blood pressure, laboratory tests (HDL, LDL, plasma 
glucose, cholesterol and triglycerides) and symptoms (CGI 
and HoNOS). 
Recommendations by various professional organizations 
concerning monitoring of anthropometric and laboratory 
variables in routine clinical practice is found in Table 1 
3.1. Measurement of Cardiometabolic Risk 
Factors 
We examine blood glucose, high-density lipoprotein 
(HDL), triglycerides, low density lipoprotein (LDL) and 
body mass index (BMI) as cardiometaolic risk markers. We 
used the definition of the components of the metabolic 
syndrome categorically as 1. High-blood glucose, defined 
as blood glucose ≥ 5.5 mmol/L; 2. Low-HDL cholesterol as 
HDL cholesterol < 1.0 in men and <1.3 mmol/L in women; 
3. High-triglycerides as triglycerides ≥ 1.7 mmol/L; 5. High 
LDL cholesterol ≥ 2.6 mmol/L; and 6. High-BMI as BMI ≥ 
25.0 kg/m2. 
We adopted these cut-off points based on the clinical cut 
points for adverse outcomes defined by the World Health 
Organization (Albert & Zimmer 1998) and ATP-III (Adult 
Treatment Panel III, 2001).  
3.2. Statistical Analysis 
Data analysis to determine the overall effectiveness of 
the intervention involves comparison of the data points in 
the control section of the wedge (pre-intervention/pre- 
education) with those in the intervention section. 
4. General Conclusion 
Morbidity and mortality from cardiometabolic risk in 
schizophrenia is higher than chance occurrence. 
Identification and management of these risk factors seem to 
be hampered by a number of barriers despite years of 
developing one guide line after another. 
There is need to re-evaluate the current knowledge, 
beliefs and practice of every one concerned with 
schizophrenia ( be they formal or informal care providers) 
and develop a comprehensive yet simple, cheap, friendly 
integrated method of simultaneously including patients 
themselves, patients relations and all health professionals 
involved with service delivery for schizophrenia in the 
cardiometabolic risk reduction technique. The 
MOMACRIS Project is designed to address this goal. 
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The protocol development and baseline data collection in 
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the writing of the research reports 
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